Received Apr 2, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | H4279 | — |
Boostrix vaccine administered instead was Infanrix; two years old patient received boostrix vaccine; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong product administered in a 2-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number H4279) for prophylaxis. Co-suspect products included DTPa (Infanrix) for prophylaxis. Previously administered products included pediarix (Received first dose on an unknown date) and pediarix (Received second dose on an unknown date). On 28-FEB-2026, the patient received the 1st dose of Boostrix. The patient did not receive Infanrix. On 28-FEB-2026, an unknown time after receiving Boostrix, the patient experienced wrong product administered (Verbatim: Boostrix vaccine administered instead was Infanrix) and inappropriate age at vaccine administration (Verbatim: two years old patient received boostrix vaccine). The outcome of the wrong product administered and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date:26-MAR-2026 Office manager reported that a two-year-old child had been mistakenly administered Boostrix instead of the intended Infanrix. This was the child's first dose of Boostrix, but it should have been the child's third DTaP dose.